Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Bullboard Posts
Comment by Haidukon May 17, 2016 9:55am
207 Views
Post# 24880411

RE:News?

RE:News?
Yes, indeed, the wording is hard to decipher and / or misleading…

When does SMB intend to release those “major milestones results…” (already known?) “… that will….” (future time) be used to “… provide scientific credibility” (no such credibility was evidenced so far?), “… in due course…” (and no longer “near-term”?)

If the results are outstanding (even if not directly mentioned as such), why is the deal not yet closed with this “third party”? Do they privilege the financial “target”, rather than the deadline?

Plus, I do not really like this dichotomy: the “third party” versus “potential partners”.

IMHO, management seems to indicate that their previous strategy has been adjusted (for unknown reasons: good or bad?) and that the initial deadline (Q2-2016) is questionable…

… and the waiting game goes on…

GLTA

Haiduk
Bullboard Posts